Inhibikase Therapeutics, Inc. business relationships
Companies named in Inhibikase Therapeutics, Inc.’s 10-K filed 2026-03-26, and public companies whose annual reports name Inhibikase Therapeutics, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.
- AEO visibility
- 4.6 / 10
- AI naming
- 2 / 100 Top 5% in its category
- Agent readiness
- 25 / 100
- AI adoption
- 0 / 100
Named in Inhibikase Therapeutics, Inc.’s annual report 1
“In May 2025, we entered into a license agreement (the "License Agreement") with ABLi Therapeutics, Inc. ("ABLi"), pursuant to which we granted ABLi an exclusive, sub-licensable, royalty-bearing license under the Licensed IP (as defined in the License Agreement) to develop, manufacture, and commercia...” SEC filing
Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.